33 One case report found that use of oral contraceptives may be significant risk factor in patients with an underlying prothrombotic disorder. 34 There is a growing body of evidence suggesting that patients with BCS should be screened for the JAK2V617F mutation. 8 , 10 Since many patients with myeloproliferative disorders are not discovered with conventional medical techniques, this could be particularly helpful for patients with BCS with no known history of a myeloproliferative disorder. 8 Recently, ethnic and geographic differences in the prevalence of JAK2V617F mutations in Western countries and in China were described.
1
—
—